Phase II evaluation of 4'-epi-doxorubicin in patients with advanced colorectal carcinoma.
4'-Epi-doxorubicin (4'-epi-DX) is a new doxorubicin derivative that is more active than the parent compound against murine sarcoma virus tumors and Lewis lung carcinoma and may be less toxic. Thirty-five patients with advanced measureable colorectal carcinoma were treated with 4'-epi-DX (85 mg/m2) every 3 weeks. The major toxic effect was leukopenia less than 2000 cells/mm3 in 28% of the patients. One of 29 patients (3%) had a partial response. At this dose and schedule, 4'-epi-DX has minimal activity in colorectal carcinoma.
D000328:Adult; D000368:Aged; D000505:Alopecia / Q000139:chemically induced; D000970:Antineoplastic Agents / Q000009:adverse effects*; D003110:Colonic Neoplasms / Q000188:drug therapy*; D004317:Doxorubicin / Q000009:adverse effects*; D004341:Drug Evaluation; D015251:Epirubicin; D005221:Fatigue / Q000139:chemically induced; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D012004:Rectal Neoplasms / Q000188:drug therapy*; D013237:Stereoisomerism; D014839:Vomiting / Q000139:chemically induced
D000970:Antineoplastic Agents; D015251:Epirubicin; D004317:Doxorubicin